Literature DB >> 12682050

Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase.

Trina L McIlhargey1, Yingying Yang, Howard Wong, John S Hill.   

Abstract

To localize the regions of lipoprotein lipase (LPL) that are responsive to activation by apoC-II, an apoC-II peptide fragment was cross-linked to bovine LPL. Following chemical hydrolysis and peptide separation, a specific fragment of LPL (residues 65-86) was identified to interact with apoC-II. The fragment contains regions of amino acid sequence dissimilarity compared with hepatic lipase (HL), a member of the same gene family that is not responsive to apoC-II. Using site-directed mutagenesis, two sets of chimeras were created in which the two regions of human LPL (residues 65-68 and 73-79) were exchanged with the corresponding human HL sequences. The chimeras consisted of an HL backbone with the suspected LPL regions replacing the corresponding HL sequences either individually (HLLPL-(65-68) and HLLPL-(73-79)) or together (HLLPLD). Similarly, LPL chimeras were created in which the candidate regions were replaced with the corresponding HL sequences (LPLHL-(77-80), LPLHL-(85-91), and LPLHLD). Using a synthetic triolein substrate, the lipase activity of the purified enzymes was measured in the presence and absence of apoC-II. Addition of apoC-II to HLLPL-(65-68) and HLLPL-(73-79) did not significantly alter their enzyme activity. However, the activity of HLLPLD increased approximately 5-fold in the presence of apoC-II compared with an increase in native LPL activity of approximately 11-fold. Addition of apoC-II to LPLHL-(77-80) resulted in approximately 10-fold activation, whereas only approximately 6- and approximately 4-fold activation of enzyme activity was observed in LPLHL-(85-91) and LPLHLD, respectively. In summary, our results have identified 11 amino acid residues in the N-terminal domain of LPL (residues 65-68 and 73-79) that appear to act cooperatively to enable substantial activation of human LPL by apoC-II.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682050     DOI: 10.1074/jbc.M300315200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  cDNA sequence and tissues expression analysis of lipoprotein lipase from common carp (Cyprinus carpio Var. Jian).

Authors:  Han-liang Cheng; Si-ping Sun; Yong-xing Peng; Xiao-yun Shi; Xin Shen; Xue-ping Meng; Zhi-guo Dong
Journal:  Mol Biol Rep       Date:  2009-09-15       Impact factor: 2.316

Review 2.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

3.  We FRET so You Don't Have To: New Models of the Lipoprotein Lipase Dimer.

Authors:  Cassandra K Hayne; Hayretin Yumerefendi; Lin Cao; Jacob W Gauer; Michael J Lafferty; Brian Kuhlman; Dorothy A Erie; Saskia B Neher
Journal:  Biochemistry       Date:  2018-01-05       Impact factor: 3.162

Review 4.  Apolipoproteins in vascular biology and atherosclerotic disease.

Authors:  Anurag Mehta; Michael D Shapiro
Journal:  Nat Rev Cardiol       Date:  2021-10-08       Impact factor: 32.419

Review 5.  Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk.

Authors:  Jila Kaberi Otarod; Ira J Goldberg
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

6.  Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.

Authors:  Toshihiro Sakurai; Akiko Sakurai; Boris L Vaisman; Marcelo J Amar; Chengyu Liu; Scott M Gordon; Steven K Drake; Milton Pryor; Maureen L Sampson; Ling Yang; Lita A Freeman; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

Review 7.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

8.  GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4.

Authors:  William K Sonnenburg; Daiguan Yu; E-Chiang Lee; Wei Xiong; Gennady Gololobov; Billie Key; Jason Gay; Nat Wilganowski; Yi Hu; Sharon Zhao; Matthias Schneider; Zhi-Ming Ding; Brian P Zambrowicz; Greg Landes; David R Powell; Urvi Desai
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

9.  Comparative analyses of lipoprotein lipase, hepatic lipase, and endothelial lipase, and their binding properties with known inhibitors.

Authors:  Ziyun Wang; Shen Li; Lidan Sun; Jianglin Fan; Zhenming Liu
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

10.  Role of adipocyte-derived lipoprotein lipase in adipocyte hypertrophy.

Authors:  Amanda M Gonzales; Robert A Orlando
Journal:  Nutr Metab (Lond)       Date:  2007-10-30       Impact factor: 4.169

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.